We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERT? platform, which is based on our Flow Electroporation? technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx?, STx?, GTx? and VLx ?; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.
MaxCyte, Inc.的外部链接
9713 Key West Ave
Suite 400
US，Maryland，Rockville，20850
Join us in Celebrating MaxCyte's 25 Years of innovation in the field of cell and gene therapy! As part of our celebration, we're inviting YOU to participate in a special poll series. Complete the weekly poll questions to join in the fun. For insights, check out our historical timeline. https://lnkd.in/eEJURwkN
此处无法显示此内容
在领英 APP 中访问此内容等
Last week, our team had the exceptional opportunity to connect with esteemed leaders in the cell and gene therapy community at the 2nd Annual Cell and Gene Therapy Symposium, held at?Children's National Hospital, in Washington, DC. This event, a cornerstone for the mid-Atlantic region, provided a platform for meaningful dialogue and collaboration. Special thanks to?Yuqi Zhu,?Diwash Acharya, PhD, Ashley Strickland-Dietz, Ph.D. and?Alfred Sloan MBA?for their invaluable participation and contributions.
Nearly 200 scientific innovators came together at this week’s Cell and Gene Therapy Symposium at the Children’s National Research & Innovation Campus, where we explored the promising future of life-changing treatments targeting diseases at the cellular level. The shared vision among experts from Maryland, Virginia and Washington, D.C., is forging a community that will save lives and create regional expertise in the next generation of rare disease treatments.? ? Kudos to our leaders at the Center for Cancer and Immunology Research – Drs. Catherine Bollard and Patrick Hanley, Ph.D. – for hosting this thought-provoking event. #CellTherapy #GeneTherapy #HealthcareInnovation
Are you interested in learning about recent breakthroughs in treating blood disorders, including sickle cell disease and immune deficiencies, with CRISPR-Cas9 technology? Watch an on-demand webinar discussing gene editing in hematopoietic stem cells, featuring a presentation from Zulema Romero Garcia, PhD, as she discusses the use of CRISPR/Cas9 technology to edit hematopoietic stem cells, aiming to correct genetic mutations and improve patient outcomes. #CRISPR #GeneEditing #SickleCellDisease #HematopoieticStemCells #Cas9 https://lnkd.in/g2WNggPZ
Join us on December 4, 2024, at MassBio in Cambridge, Massachusetts, for an insightful seminar on intelligent manufacturing and reliable gene delivery tools. Presented by OmniaBio and MaxCyte, this seminar will delve into the latest advancements in cell and gene therapy development and manufacturing featuring presentations from Neil Blackburn, PhD, and Sakthi Moorthy, PhD, from Omnia Bio. Gain valuable insights into how MaxCyte and OmniaBio's innovative platforms enable the efficient engineering of primary cells, stem cells and other cell lines. We'll share case studies on how we've helped accelerate and de-risk cell and gene therapy development, paving the way for clinical and efficacious therapies for patients. Register for the virtual session: https://bit.ly/3AZ8S4o Register for the in-person session: https://bit.ly/3CDtcch Connect with us: Jess Keeley #CellTherapy #GeneTherapy #Biotech #OmniaBio #MaxCyte #Seminar #MassBioHub
Celebrating 25 years in the field of cell and gene therapy! This incredible milestone reflects our dedication and commitment to groundbreaking innovation. Here's to a quarter-century of progress and achievement! Swipe through a historical carousel to see the milestones achieved over the years. #MaxCyteSparksInnovation https://lnkd.in/eEJURwkN
The latest Cell & Gene Newsletter delves into groundbreaking advancements in electroporation technology. These innovations are not just incremental improvements; they are transformative leaps that are driving the development of next-generation cell-based therapies. This progress offers unprecedented hope for treating diseases that were once deemed incurable. As we continue to push the boundaries of what’s possible in genetic engineering and cellular therapy, new electroporation technologies are enhancing the efficiency, scalability, and cost-effectiveness of cell engineering. This paves the way for more accessible and effective treatments. Stay informed and inspired by these advancements that are shaping the future of medicine. Together, we are on the brink of a new era in healthcare. https://bit.ly/3YAzJf8
As MaxCyte marks its 25th Anniversary, we reflect on our journey to becoming a pioneer in non-viral cell engineering through our leading electroporation technology. Our unwavering dedication to customer service has been a cornerstone of our success. From the outset, our ambition was to forge a path of significant influence and innovation. Now, as we celebrate our achievements, we renew our pledge to support developers in their quest to create groundbreaking therapies. Looking ahead, we are excited for the opportunities to further contribute to the field of cell and gene therapy by helping our partners to provide solutions to cure previously untreatable diseases, remaining steadfast in our goal to enhance human health globally. Join us as we celebrate our 25th Anniversary by watching a video recap of our first 25 years and our vision on the future of MaxCyte and cell therapy. #MaxCyteSparksInnovation https://lnkd.in/eYvxQDzy
Join Us for an Exciting Webinar on Next-Generation Genetic Discovery Systems, hosted by The CRISPR Journal. This webinar will feature a presentation by Theo Roth, MD, PhD, from Stanford University, one of the developers of pooled knock-in screening, as our speaker. Dr. Roth will provide an insightful overview of this cutting-edge platform and discuss the advantages of non-viral genome targeting. Don’t miss this opportunity to learn from a leading expert in the field! Register now for this free webinar: https://hubs.li/Q02Wk2bW0 We look forward to seeing you there! #Webinar #GeneticDiscovery #CRISPR #MaxCyte #Biotech #GenomeEditing #HumanImmuneCells
We are excited to join The CRISPR Journal for a webinar on next-generation genetic discovery systems in human immune cells. This webinar will be led by Theo Roth, MD, PhD, a pioneer in pooled knock-in screening, who will discuss the advantages of non-viral genome targeting. Register today: https://hubs.li/Q02Wk2bW0
DON'T MISS OUT! Next-Generation Genetic Discovery Systems in Human Immune Cells In this November 18th webinar hosted by The CRISPR Journal, one of the developers of pooled knock-in screening, Dr. Theo Roth (Stanford University), will present an overview of this platform and the advantages of non-viral genome targeting. Register now to join us for this free webinar sponsored by MaxCyte, Inc.: https://hubs.li/Q02Wk2bW0
MaxCyte Celebrates 25 Years of Innovation in Cell Engineering Since 1999, MaxCyte has been a driving force behind pioneering cell and gene therapy projects, providing non-viral cell engineering solutions that have transformed the landscape of biomedical research. Over the past 25 years, our innovative Flow Electroporation? technology has powered the launch of a suite of products within our ExPERT? platform. As we look to the future, we remain committed to pushing the boundaries of cell-based medicine, empowering our partners, and ultimately improving the lives of patients around the world. Here's to the next era of breakthroughs in cell and gene therapy! Read more about our journey: https://lnkd.in/emJs45Qq